Sex and racial differences in pharmacological response: where is the evidence? Pharmacogenetics, pharmacokinetics, and pharmacodynamics.
暂无分享,去创建一个
[1] M. Hughes,et al. Pharmacokinetics of Saquinavir plus Low-Dose Ritonavir in Human Immunodeficiency Virus-Infected Pregnant Women , 2004, Antimicrobial Agents and Chemotherapy.
[2] P. Pennell,et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine , 2004, Neurology.
[3] A. Rane,et al. Plasma concentration — effect relationship of metoprolol during and after pregnancy , 2004, European Journal of Clinical Pharmacology.
[4] U. Gundert-Remy,et al. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations , 2004, European Journal of Clinical Pharmacology.
[5] W. Jusko,et al. Longitudinal effects of pregnancy on the pharmacokinetics of theophylline , 2004, European Journal of Clinical Pharmacology.
[6] B. Ring,et al. Hepatic CYP2B6 Expression: Gender and Ethnic Differences and Relationship to CYP2B6 Genotype and CAR (Constitutive Androstane Receptor) Expression , 2003, Journal of Pharmacology and Experimental Therapeutics.
[7] H. Lennernäs,et al. Multiple transport mechanisms involved in the intestinal absorption and first‐pass extraction of fexofenadine , 2003, Clinical pharmacology and therapeutics.
[8] U. Schwarz,et al. Clinical relevance of genetic polymorphisms in the human CYP2C9 gene , 2003, European journal of clinical investigation.
[9] I. Cascorbi. Pharmacogenetics of cytochrome P4502D6: genetic background and clinical implication , 2003, European journal of clinical investigation.
[10] Peter Neuhaus,et al. Sex is a major determinant of CYP3A4 expression in human liver , 2003, Hepatology.
[11] P. Pennell. Antiepileptic drug pharmacokinetics during pregnancy and lactation , 2003, Neurology.
[12] K. Stȩpniewska,et al. The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria , 2003, European Journal of Clinical Pharmacology.
[13] K. Stȩpniewska,et al. Pregnancy and use of oral contraceptives reduces the biotransformation of proguanil to cycloguanil , 2003, European Journal of Clinical Pharmacology.
[14] S. Rathore,et al. Digoxin and quality of life in heart failure. , 2003, Journal of cardiac failure.
[15] Ernest Hodgson,et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. , 2003, Pharmacogenetics.
[16] J. Lukas,et al. Population pharmacokinetics of netilmicin in short-term prophylactic treatment. , 2003, British journal of clinical pharmacology.
[17] H. Lee,et al. Gender Differences in the Membrane Transport of Endogenous and Exogenous Compounds , 2003, Pharmacological Reviews.
[18] S. Hayashi,et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women , 2003, AIDS.
[19] U. Ekblad,et al. Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation , 2003, Clinical pharmacology and therapeutics.
[20] H. Krumholz,et al. Digoxin therapy for heart failure: safe for women? , 2003, Italian heart journal : official journal of the Italian Federation of Cardiology.
[21] Harlan M Krumholz,et al. Association of serum digoxin concentration and outcomes in patients with heart failure. , 2003, JAMA.
[22] J. Schwartz. The Influence of Sex on Pharmacokinetics , 2003, Clinical pharmacokinetics.
[23] A. Katchman,et al. In vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectifier potassium currents in orchiectomized male rabbits. , 2003, Cardiovascular research.
[24] E. Schuetz,et al. Genetic contribution to variable human CYP3A-mediated metabolism. , 2002, Advanced drug delivery reviews.
[25] L. Benet,et al. Sex‐related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P‐glycoprotein , 2002, Clinical pharmacology and therapeutics.
[26] Harlan M Krumholz,et al. Sex-based differences in the effect of digoxin for the treatment of heart failure. , 2002, The New England journal of medicine.
[27] M. Anthony,et al. Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: Part I. , 2002, Journal of women's health & gender-based medicine.
[28] I. Leppik,et al. Lamotrigine clearance during pregnancy , 2002, Neurology.
[29] J. Daling,et al. Body Weight and Risk of Oral Contraceptive Failure , 2002, Obstetrics and gynecology.
[30] L. Benet,et al. Changes in plasma protein binding have little clinical relevance , 2002, Clinical pharmacology and therapeutics.
[31] G. Anderson. Sex differences in drug metabolism: cytochrome P-450 and uridine diphosphate glucuronosyltransferase. , 2002, The journal of gender-specific medicine : JGSM : the official journal of the Partnership for Women's Health at Columbia.
[32] D. Flockhart,et al. Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism , 2002, Clinical pharmacokinetics.
[33] Hartmut Derendorf,et al. How Important Are Gender Differences in Pharmacokinetics? , 2002, Clinical pharmacokinetics.
[34] L. Mofenson,et al. Pharmacokinetics of Saquinavir-SGC in HIV-Infected Pregnant Women , 2001, HIV clinical trials.
[35] Joo-Youn Cho,et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin , 2001, Clinical pharmacology and therapeutics.
[36] R. Kim,et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans , 2001, Clinical pharmacology and therapeutics.
[37] I. Miyakawa,et al. The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N‐acetyltransferase activities in humans , 2001, Clinical pharmacology and therapeutics.
[38] J. Pezzullo,et al. Drug-induced QT prolongation in women during the menstrual cycle. , 2001, JAMA.
[39] Influence of gender and oral contraceptives on CYP2D6 and CYP2C19 activity in healthy volunteers. , 2001, British journal of clinical pharmacology.
[40] M. Drici,et al. Is Gender a Risk Factor for Adverse Drug Reactions? , 2001, Drug safety.
[41] Donald J. Schuirmann,et al. Pharmacokinetic analysis of bioequivalence trials: Implications for sex‐related issues in clinical pharmacology and biopharmaceutics , 2000, Clinical pharmacology and therapeutics.
[42] M. Thase,et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. , 2000, The American journal of psychiatry.
[43] F. Aweeka,et al. Pharmacokinetics of indinavir in HIV-positive pregnant women. , 2000, AIDS.
[44] H. Saito,et al. Hormonal regulation of organic cation transporter OCT2 expression in rat kidney , 2000, FEBS letters.
[45] D. Flockhart,et al. Greater quinidine‐induced QTc interval prolongation in women , 2000, Clinical pharmacology and therapeutics.
[46] F. Follath,et al. Epidemiology of drug exposure and adverse drug reactions in two swiss departments of internal medicine. , 2000, British journal of clinical pharmacology.
[47] R. Kim,et al. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. , 1999, Pharmacogenetics.
[48] D. Nicolau,et al. Population Pharmacokinetics of Continuous Infusion Ceftazidime , 1999, Clinical pharmacokinetics.
[49] C. Beasley,et al. Olanzapine. Pharmacokinetic and pharmacodynamic profile. , 1999, Clinical pharmacokinetics.
[50] R. A. Zeeuw,et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences , 1999, European Journal of Clinical Pharmacology.
[51] S. Sviri,et al. Phenotypic‐genotypic analysis of CYP2C19 in the Jewish Israeli population , 1999, Clinical pharmacology and therapeutics.
[52] M. Jann,et al. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. , 1999, The Journal of clinical psychiatry.
[53] N. Vermeulen,et al. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. , 1999, Critical reviews in toxicology.
[54] S. Knowles,et al. Gender Differences in Adverse Drug Reactions , 1998, Journal of clinical pharmacology.
[55] U. Elkayam,et al. Pharmacokinetic and Pharmacodynamic Evaluation of Atenolol during and after Pregnancy , 1998, Pharmacotherapy.
[56] J. Miners,et al. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. , 1998, British journal of clinical pharmacology.
[57] G. Koren,et al. Pharmacokinetic Changes During Pregnancy and Their Clinical Relevance , 1997, Clinical pharmacokinetics.
[58] M. Wadelius,et al. Induction of CYP2D6 in pregnancy , 1997, Clinical pharmacology and therapeutics.
[59] D W Nebert,et al. The UDP glycosyltransferase gene superfamily: recommended nomenclature update based on evolutionary divergence. , 1997, Pharmacogenetics.
[60] S. Ekins,et al. Examination of purported probes of human CYP2B6. , 1997, Pharmacogenetics.
[61] G. Granneman,et al. Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic Interactions , 1997, Clinical pharmacokinetics.
[62] H. Yamazaki,et al. In vivo and in vitro characterization of CYP2E1 activity in Japanese and Caucasians. , 1996, The Journal of pharmacology and experimental therapeutics.
[63] J. Goldstein,et al. Genetic polymorphism of S-mephenytoin 4'-hydroxylation in African-Americans. , 1996, Pharmacogenetics.
[64] K. Brøsen,et al. Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. , 1996, Therapeutic drug monitoring.
[65] B. Reigner,et al. Factors influencing elimination and distribution of fleroxacin: metaanalysis of individual data from 10 pharmacokinetic studies , 1996, Antimicrobial agents and chemotherapy.
[66] E. Schuetz,et al. Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. , 1995, The Journal of pharmacology and experimental therapeutics.
[67] B. Burchell,et al. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. , 1995, Life sciences.
[68] F. Berthou,et al. Cytochrome P450 2E1 genotype and chlorzoxazone metabolism in healthy and alcoholic Caucasian subjects. , 1995, Pharmacogenetics.
[69] L. Bertilsson,et al. Geographical/Interracial Differences in Polymorphic Drug Oxidation , 1995, Clinical pharmacokinetics.
[70] N. Narayanan,et al. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. , 1995, Pharmacogenetics.
[71] W. Jaeger,et al. Clinical importance of hepatic cytochrome P450 in drug metabolism. , 1995, Drug metabolism reviews.
[72] F. Aoki,et al. Chronic tobacco smoking and gender as variables affecting amantadine disposition in healthy subjects. , 1995, British journal of clinical pharmacology.
[73] R. Slaughter,et al. Vancomycin Pharmacokinetics in a Patient Population: Effect of Age, Gender, and Body Weight , 1994, Therapeutic drug monitoring.
[74] D. Schrenk,et al. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. , 1994, Pharmacogenetics.
[75] H. Yamazaki,et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. , 1994, The Journal of pharmacology and experimental therapeutics.
[76] J. Schwartz,et al. Aging of women alters S‐verapamil pharmacokinetics and pharmacodynamics , 1994, Clinical pharmacology and therapeutics.
[77] T. Tomson,et al. Epilepsy and Pregnancy: A Prospective Study of Seizure Control in Relation to Free and Total Plasma Concentrations of Carbamazepine and Phenytoin , 1994, Epilepsia.
[78] B. Burchell,et al. The Uridine Diphosphate Glucuronosyltransferase Multigene Family: Function and Regulation , 1994 .
[79] M. Lehmann,et al. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs , 1993 .
[80] A. Nafziger,et al. Gender differences in hepatic induction and inhibition of theophylline pharmacokinetics and metabolism. , 1993, The Journal of laboratory and clinical medicine.
[81] F. Aoki,et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine , 1993, Clinical pharmacology and therapeutics.
[82] M. Relling,et al. Racial and gender differences in N‐acetyltransferase, xanthine oxidase, and CYP1A2 * activities , 1992, Clinical pharmacology and therapeutics.
[83] E. Yukawa,et al. Digoxin Population Pharmacokinetics from Routine Clinical Data: Role of Patient Characteristics for Estimating Dosing Regimens , 1992, The Journal of pharmacy and pharmacology.
[84] K. Pittman,et al. Effects of age and gender on pharmacokinetics of cefepime , 1992, Antimicrobial Agents and Chemotherapy.
[85] J. Gross,et al. Effect of age and sex on glomerular filtration rate measured by 51Cr-EDTA. , 1992, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[86] S. Wrighton,et al. The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.
[87] B. Tang,et al. Caffeine as a metabolic probe: Validation of its use for acetylator phenotyping , 1991, Clinical pharmacology and therapeutics.
[88] F. Kristjánsson,et al. Disposition of alprazolam in human volunteers. Differences between genders. , 1991, Acta pharmaceutica Nordica.
[89] T. Ockhuizen,et al. Application of a three-compartment model to a study of the effects of sex, alcohol dose and concentration, exercise and food consumption on the pharmacokinetics of ethanol in healthy volunteers. , 1991, Alcohol and alcoholism.
[90] B. Zuckerman,et al. High blood alcohol levels in women. , 2010, The New England journal of medicine.
[91] H. Wynne,et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases , 1990, Clinical pharmacology and therapeutics.
[92] C. J. Sells,et al. Pharmacokinetics of anticonvulsants in pregnancy: Alterations in plasma protein binding , 1990, Epilepsy Research.
[93] C. Lieber,et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. , 1990, The New England journal of medicine.
[94] P. Vlasses,et al. Effect of food on the absorption of enteric‐coated aspirin: Correlation with gastric residence time , 1987, Clinical pharmacology and therapeutics.
[95] J. Puig,et al. Sex differences in uric acid metabolism in adults: Evidence for a lack of influence of estradiol-17β (E2) on the renal handling of urate , 1986 .
[96] C. Regårdh,et al. Pregnancy‐induced increase in metoprolol metabolism , 1985, Clinical pharmacology and therapeutics.
[97] D. Greenblatt,et al. Diazepam kinetics in relation to age and sex. , 1981, Pharmacology.
[98] J. Davison,et al. Renal hemodynamics and tubular function in normal human pregnancy , 1980 .
[99] G. Levy,et al. Serum protein binding of drugs during and after pregnancy in humans , 1980, Clinical pharmacology and therapeutics.
[100] H. Valkenburg,et al. THE DISTRIBUTION OF SERUM URIC ACID VALUES IN A POPULATION UNSELECTED AS TO GOUT OR HYPERURICEMIA: TECUMSEH, MICHIGAN 1959-1960. , 1965 .